Newly built manufacturing plants also offer Hanmi an ability to produce several key innovative drug APIs and
intermediates. Hanmi has been working with its partners to export key innovative drug APIs and intermediates to global market. Hanmi is also quite interested in CMO opportunities with its potential global partners for Cephalosporin API, finished product, both oral and injectables, as well as innovative drug APIs and key intermediates.

Hanmi also has been active in working with global partners in exporting its IMDs (incrementally modified drugs) such as esomeprazole, sibutramine, clopidogrel, amlodipine, atorvastatin, etc. Hanmi has been working vigorously to find business partners in other parts of the world for its numerous IMDs.
Hanmi has been searching and considering partnership opportunities with its Platform technologies and products in its developmental pipeline which includes LAPSCOVERY (Long-Acting Protein/Peptide Technology) and ORASCOVERY (Oral Oncology Product Technology).